Regeneron Pharmaceuticals (REGN) Barclays 28th Annual Global Healthcare Conference summary

Key product performance and launches

• Dupixent achieved $17.8 billion in sales last year, up 32% year-over-year, with continued growth across all nine FDA-approved indications, including recent launches in chronic spontaneous urticaria and COPD.

• COPD launch for Dupixent is progressing well, with robust payer coverage and strong enthusiasm from pulmonologists, improving patient outcomes and quality of life.

• EYLEA HD now represents nearly half of the EYLEA franchise revenues, with recent FDA label enhancements and anticipated prefilled syringe approval expected to further boost market share.

• Lynozyfic, approved for late-line myeloma, is showing early positive uptake and is being evaluated for broader use in earlier lines and precursor conditions.

Competitive positioning and life cycle management

• Dupixent maintains a strong competitive edge due to its dual mode of action, broad indications, and established efficacy and safety profile, with ongoing monitoring of emerging competition.

• Life cycle management for Dupixent includes development of long-acting IL-4 and IL-13 antibodies, aiming for less frequent dosing and continued market leadership.

• EYLEA HD is positioned as the most flexible and durable anti-VEGF therapy, with the prefilled syringe expected to drive further adoption.

• EYLEA is expected to see sequential declines due to biosimilar competition, but conversion efforts are underway to transition patients to EYLEA HD.

Pipeline and future catalysts

• Near-term catalysts include pivotal readouts for fianlimab plus Libtayo in metastatic melanoma, geographic atrophy, and PNH, with key data expected throughout this year.

• Obesity program with olatorepatide demonstrated 19% weight loss in pivotal China data, with U.S. and ex-China Phase III studies planned to start later this year.

• Co-formulation of olatorepatide with alirocumab aims to address both weight loss and LDL cholesterol reduction, targeting an unmet need in the obesity market.

• Lynozyfic's opportunity could expand significantly as it moves into earlier lines of myeloma, with the U.S. patient population doubling from fourth-line to third-line settings.

• Additional pipeline milestones include Factor XI pivotal data in VTE expected in the first half of next year and ongoing progress in geographic atrophy and PNH.